Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosis* of 1 of the following by radiological features and clinical presentation:

- Bronchoalveolar carcinoma (BAC)

- Diffuse or ground glass appearance

- Adenocarcinoma with bronchoalveolar features

- BAC with focal invasion NOTE: *Histological confirmation (excluding fine needle
aspiration or bronchial brushings or washings) is required after the tumor
tissue has been procured and the vaccine has been produced

- Selected stage IIIB (due to malignant pleural effusion) OR stage IV disease

- Measurable or nonmeasurable disease (e.g., diffuse infiltrative process) by CT scan
of the chest both before and after tumor tissue procurement for vaccine

- Not a candidate for curative resection

- Tumor accessible for tissue procurement via thoracentesis or a surgical procedure

- If a pleural effusion is the source of tumor tissue, at least 600 mL of fluid
must be available for vaccine manufacture

- Resection of brain metastases may be used for vaccine processing

- Surgery must be done after study entry

- Asymptomatic previously treated (e.g., surgical resection or radiotherapy) brain
metastases allowed provided the patient is neurologically stable

- No active or impending spinal cord compression or evidence of pericardial tamponade

PATIENT CHARACTERISTICS:

Age

- Over 18

Performance status

- Zubrod 0-1

Life expectancy

- Not specified

Hematopoietic

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- CD4 count greater than 200/mm^3

- No bleeding disorder

Hepatic

- Bilirubin no greater than 1.5 times upper limit of normal (ULN) (3 times ULN if liver
metastases are present)

- SGOT or SGPT no greater than 2.5 times ULN (5 times ULN if liver metastases are
present)

- Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if bone metastases
are present)

Renal

- Not specified

Cardiovascular

- See Disease Characteristics

- Patients requiring surgery for tumor tissue procurement must meet the following
criteria:

- Pulmonary artery systolic pressure < 40 mm Hg by echocardiogram*

- LVEF > 40%

- No symptomatic congestive heart failure

- No thrombolic disorder

- No unstable angina pectoris

- No cardiac arrhythmia NOTE: *Not needed if patient has no tricuspid regurgitation

Pulmonary

- No pulmonary hypertension

- No significant baseline hypoxia (i.e., O_2 saturation less than 90% OR requires
greater than 2 L/min of supplemental O_2 via nasal cannula) by an oxygen saturation
test

- No postobstructive pneumonia

- Patients requiring thoracoscopic surgery or thoracotomy for tumor tissue procurement
must meet the following criteria:

- Alveolar partial pressure of CO_2 < 45 mm Hg

- Predicted postresection FEV_1 ≥ 1.0 L

- DLCO > 50% of predicted

Immunologic

- No active immune or autoimmune disease

- No systemic lupus erythematosus

- No sarcoiditis

- No rheumatoid arthritis

- No glomerulonephritis

- No vasculitis

- No serious infection

- No hypersensitivity to any of the following:

- Sargramostim (GM-CSF)

- Pentastarch

- Gentamicin

- Human serum albumin

- Dimethyl sulfoxide

- Porcine trypsin

- Fetal bovine serum

- Recombinant benzonase

- Other components of the vaccine or CG6444 adenoviral vector used in this study

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No poor nutritional status

- No psychiatric illness or social situation that would preclude study compliance or
increase operative risk

- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
stage I or II cancer currently in complete remission

- No other concurrent uncontrolled illness

PRIOR CONCURRENT THERAPY:

Biologic therapy

- More than 4 weeks since prior biologic therapy

- No prior gene therapy, including adenoviral-based therapy

Chemotherapy

- More than 4 weeks since prior chemotherapy

- No prior regional chemotherapy administered through the pulmonary artery (if
resection of the tumor in the treated lobe is planned)

Endocrine therapy

- More than 14 days since prior systemic corticosteroids

- No concurrent steroids

Radiotherapy

- See Disease Characteistics

- More than 4 weeks since prior radiotherapy

- Disease must be outside the areas of prior radiotherapy OR clear progression at
prior irradiated sites must be documented

- No prior radiotherapy to the tumor mass targeted for resection

Surgery

- See Disease Characteristics

- More than 7 days since prior surgery and recovered

Other

- More than 2 weeks since prior epidermal growth factor receptor inhibitors

- No other concurrent nonprotocol-specified treatment

- No concurrent immunosuppressants

- No concurrent chronic anticoagulation therapy